Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
暂无分享，去创建一个
M. Kudo | A. Zhu | R. Finn | T. Yau | B. Daniele | Y. Chao | A. Cheng | J. Knox | S. Chan | H. Lim | M. Garrido | A. Siegel | S. Ebbinghaus | S. Ogasawara | P. Merle | B. Ryoo | V. Breder | Ho Yeong Lim | M. Bouattour | J. Edeline | E. Chen